Why Hims & Hers Health Stock Is Falling
Why Hims & Hers Health Stock Is Falling
爲什麼Hims & Hers Health股票在下跌
Eli Lilly and Co (NYSE:LLY) today announced an expansion in the availability of its obesity treatment, Zepbound (tirzepatide), which is now offered in 2.5 mg and 5 mg single-dose vials at a discounted price.
禮來（NYSE:LLY）今日宣佈擴大其肥胖治療藥物Zepbound（替重匹肽）的可獲性，現在以2.5毫克和5毫克單劑瓶以優惠價格提供。
The announcement has sent shockwaves through the telehealth and wellness industry, with Hims & Hers Health Inc (NYSE:HIMS) seeing a 5.05% drop to $15.24 during Tuesday's session amid possible competition concerns.
這一公告在遠程健康和健康行業引起了轟動，Hims & Hers Health Inc（NYSE:HIMS）在週二的交易中看到股價下跌5.05%，至15.24美元，可能是因爲競爭擔憂。
Zepbound Enters the Market with Competitive Pricing: Lilly's new Zepbound single-dose vials are priced at a 50% or greater discount compared to other incretin (GLP-1) medicines for obesity, with a four-week supply of...
Zepbound以具有競爭力的定價進入市場：Lilly的新Zepbou...
登入免費觀看全文
登入/註冊